What NRX-100 and NRX-101 Could Mean for Suicide-Focused Depression Carement
Medically Reviewed by Mark Hrymoc, M.D., Chief Medical Officer, double-board certified in General & Addiction Psychiatry Suicidal ideation in major depressive disorder and bipolar depression remains a public health emergency, with U.S. deaths by suicide reaching historically high levels in recent years. Against this backdrop, NRx Pharmaceuticals has advanced two investigational agents that target this gap: NRX-100, a preservative-free intravenous ketamine, and NRX-101, an oral fixed-dose combination of D-cycloserine and lurasidone. Understanding how FDA pathways such as Fast Track and Accelerated Approval work, and where these programs may apply, helps clarify what patients, families, and clinicians might expect as development moves forward. Where NRX-100 and NRX-101 Fit Clinically NRX-100 is being studied for rapid relief of acute suicidal ideation in depression, including bipolar depression. Ketamine’s rapid antidepressant effect is well documented, but its clinical use has been limited by temporary benefit and the need for monitored infusion. A proprietary, preservative-free …